Menu Search
Equities

Tanvex BioPharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TANVF:PKL

Tanvex BioPharma Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.0306
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tanvex BioPharma, Inc. is a Cayman Islands-based contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company. The Company specializes in research, product development, manufacture, and commercialization of biologic and biosimilar drugs. It has expertise in all areas, such as strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and warehousing, sales and distribution. The Company's CDMO services operate under the name Bora Biologics. The Company’s product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. It deploys a range of Current Good Manufacturing Practice (cGMP) biologics manufacturing capabilities.

  • Revenue in TWD (TTM)224.83m
  • Net income in TWD-1.36bn
  • Incorporated2013
  • Employees133.00
  • Location
    Tanvex BioPharma IncGrand PavilionHibiscus Way, 802 West Bay RoadP.O. Box 31119GRAND CAYMAN KY1-1205Cayman IslandsCYM
  • Websitehttps://www.tanvex.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.